Tag Archive for: pulmonary embolism

Posts

Article of the Month: Guideline of Guidelines – Thromboprophylaxis for Urological Surgery

Every Month the Editor-in-Chief selects an Article of the Month from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full article, which is freely available to all readers for at least 30 days from the time of this post.

In addition to the article itself, there is an accompanying editorial written by a prominent member of the urological community. This blog is intended to provoke comment and discussion and we invite you to use the comment tools at the bottom of each post to join the conversation.

Finally, the third post under the Article of the Week heading on the homepage will consist of additional material or media. This week we feature a video from Kari Tikkinen, discussing his paper.

If you only have time to read one article this week, it should be this one.

Guideline of guidelines: thromboprophylaxis for urological surgery

Philippe D. Violette*, Rufus Cartwright†‡, Matthias Briel§, Kari A.O. Tikkinen¶ and Gordon H. Guyatt**,

 

*Division of Urology, Department of Surgery, Woodstock Hospital, Woodstock, ON, Canada, † Department of Epidemiology and Biostatistics, Imperial College London, London, UK, Department of Urogynaecology, St. MaryHospital, London, UK, §Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel, Basel, Switzerland, Departments of Urology and Public Health, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, **Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada, and ††Department of Medicine, McMaster University, Hamilton, ON, Canada

 

 

Decisions regarding thromboprophylaxis in urologic surgery involve a trade-off between decreased risk of venous thromboembolism (VTE) and increased risk of bleeding. Both patient- and procedure-specific factors are critical in making an informed decision on the use of thromboprophylaxis. Our systematic review of the literature revealed that existing guidelines in urology are limited. Recommendations from national and international guidelines often conflict and are largely based on indirect as opposed to procedure-specific evidence. These issues have likely contributed to large variation in the use of VTE prophylaxis within and between countries. The majority of existing guidelines typically suggest prolonged thromboprophylaxis for high-risk abdominal or pelvic surgery, without clear clarification of what these procedures are, for up to 4 weeks post-discharge. Existing guidance may result in the under-treatment of procedures with low risk of bleeding and the over-treatment of oncological procedures with low risk of VTE. Guidance for patients who are already anticoagulated are not specific to urological procedures but generally involve evaluating patient and surgical risks when deciding on bridging therapy. The European Association of Urology Guidelines Office has commissioned an ad hoc guideline panel that will present a formal thromboprophylaxis guideline for specific urological procedures and patient risk factors.

AOTM Key Points

 

Editorial: Optimal Thromboprophylaxis Remains a Challenge

The ‘Guideline of guidelines: thromboprophylaxis for urological surgery’, published in this month’s issue of BJUI by Violette et al. [1], addresses a critical issue in urological practice and offers a comprehensive overview of available guidelines. Many urological surgeries, especially cancer surgeries, present a significant risk of thromboembolism, as well as bleeding. Therefore, urological surgeons should be well educated in the matter in order to be able to offer optimal prophylaxis to patients. Reading through the current recommendations and guidelines, one realises the wide variety of possible ways to risk stratify a patient, but also the large differences in opinions on how and when to offer prophylaxis. Consequently, even members within the same national society treat their patients in completely different ways.

The ideal recommendation will have to be individualised, taking thromboembolic and bleeding risk into account for each individual patient and specific surgery type. This stratification of patients not only presents a challenge in clinical practice but also for the design of meaningful clinical trials. As many medical questions regarding thromboprophylaxis remain unanswered, the currently available recommendations are based on our pathophysiological understanding and remain eminence-based, rather than evidence-based.

For many years, the ‘Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines’ [2] were viewed as the most respected guidelines in surgery. They include recommendations for a wide variety of surgical procedures, including urological surgeries. With an ageing population, our patients will more often be on anticoagulant treatment before surgery. While most guidelines still recommend stopping the anticoagulant treatment and bridging with heparin, new evidence from randomised controlled trials [3, 4] indicate that bridging by heparin significantly increases the risk for major bleeding without reducing the thromboembolic risk in most patients. Despite a recent appeal by internists and cardiologists [5], revised guidelines from the American College of Chest Physicians to replace the partially outdated recommendations have yet to be published. As mentioned by Violette et al. [1] in their current review, bridging should probably only be offered to a limited number of patients with a very high risk of thromboembolic complications.

The European Association of Urology has recognised the problem and presented the prospect of providing a guideline on thromboprophylaxis for urological procedures later this year. Looking at the landscape of available high-quality publications it will still be highly challenging to provide clear recommendations for urological surgeries. The key to a comprehensive application will be the clinical practicality. With this review, the authors have set the stage to a critical review of the recommendations from a urological point of view.

 

Daniel Eberli
University and University Hospital of Zurich, Zurich, Switzerland

 

References

 

1 Violette PD, Cartwright R, Briel M, Tikkinen KAO, Guyatt GHGuideline of guidelines: thromboprophylaxis for urological surgery. BJU Int 2016; 118: 35158

 

 

 

4 Douketis JD, Spyropoulos AC, Kaatz S et al. Perioperative bridging anticoagulation in patients with atrial brillation. N Engl J Med 2015; 373: 82333

 

 

6 Devereaux PJ, Mrkobrada M, Sessler DI et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014; 370: 1494503

 

Video: Guideline of Guidelines – Thromboprophylaxis for Urological Surgery

Guideline of guidelines: thromboprophylaxis for urological surgery

Philippe D. Violette*, Rufus Cartwright†‡, Matthias Briel§, Kari A.O. Tikkinen¶ and Gordon H. Guyatt**,

 

*Division of Urology, Department of Surgery, Woodstock Hospital, Woodstock, ON, Canada, † Department of Epidemiology and Biostatistics, Imperial College London, London, UK, Department of Urogynaecology, St. MaryHospital, London, UK, §Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel, Basel, Switzerland, Departments of Urology and Public Health, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, **Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada, and ††Department of Medicine, McMaster University, Hamilton, ON, Canada
Decisions regarding thromboprophylaxis in urologic surgery involve a trade-off between decreased risk of venous thromboembolism (VTE) and increased risk of bleeding. Both patient- and procedure-specific factors are critical in making an informed decision on the use of thromboprophylaxis. Our systematic review of the literature revealed that existing guidelines in urology are limited. Recommendations from national and international guidelines often conflict and are largely based on indirect as opposed to procedure-specific evidence. These issues have likely contributed to large variation in the use of VTE prophylaxis within and between countries. The majority of existing guidelines typically suggest prolonged thromboprophylaxis for high-risk abdominal or pelvic surgery, without clear clarification of what these procedures are, for up to 4 weeks post-discharge. Existing guidance may result in the under-treatment of procedures with low risk of bleeding and the over-treatment of oncological procedures with low risk of VTE. Guidance for patients who are already anticoagulated are not specific to urological procedures but generally involve evaluating patient and surgical risks when deciding on bridging therapy. The European Association of Urology Guidelines Office has commissioned an ad hoc guideline panel that will present a formal thromboprophylaxis guideline for specific urological procedures and patient risk factors.

 

Intra-operative pulmonary embolism secondary to dislodged tumor thrombus from synovial sarcoma of the kidney

Primary synovial sarcoma (PSS) of the kidney is a rare occurrence, with preoperative diagnosis difficult to distinguish from other renal neoplasms. Presented here is the case of a patient who underwent elective left laparoscopic nephrectomy for a 6-cm renal mass. Intra-operatively, she decompensated into PEA from multiple pulmonary emboli secondary to dislodged tumor thrombus requiring emergent sternotomy and embolectomy after placing the patient on cardiopulmonary bypass. Patient survived the surgery and has been placed on adriamycin, ifosfomide, mesna (AIM) chemotherapy. However, no definitive treatment of renal synovial sarcoma exists and prognosis is bleak despite primary surgical resection, chemotherapy, or radiotherapy.

Authors: Zhao, Philip;  Mikkilineni, Nina; Johnson, Kelly; Ankem, Murali
Corresponding Author: Philip Zhao MD, Division of Urology, Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA. Email: [email protected]

 


Abstract

Primary synovial sarcoma (PSS) of the kidney is a rare occurrence, with preoperative diagnosis difficult to distinguish from other renal neoplasms. Presented here is the case of a patient who underwent elective left laparoscopic nephrectomy for a 6-cm renal mass. Intra-operatively, she decompensated into PEA from multiple pulmonary emboli secondary to dislodged tumor thrombus requiring emergent sternotomy and embolectomy after placing the patient on cardiopulmonary bypass. Patient survived the surgery and has been placed on adriamycin, ifosfomide, mesna (AIM) chemotherapy. However, no definitive treatment of renal synovial sarcoma exists and prognosis is bleak despite primary surgical resection, chemotherapy, or radiotherapy.

Introduction

Synovial sarcoma of the kidney was reported first by Faria et al. and Argani et al. in the beginning of the twenty-first century as a distinct subset of the embryonal sarcoma of the kidney [1,2]. Although synovial tumors occur primarily in the para-articular joints of extremities, they have been encountered in the lungs, mediastinum, heart, pharynx/larynx, kidneys, and other organs. Primary renal synovial sarcoma is extremely rare, with less than thirty-five cases reported in the literature [3, 4]. Its diagnosis cannot be based on imaging studies alone – it looks similar to other renal neoplasms on CT or MRI scans, but must be confirmed by molecular and cytogenetic analysis demonstrating the chromosomal translocation of t(X;18)(p11;q11) [2]. The disease is clinically aggressive and because of the paucity of cases, there are no optimal treatment plans except complete resection and a combination of adjuvant chemotherapy or radiotherapy [5]. We present a case of PSS of the kidney that, during nephrectomy, embolized the pulmonary arterial system, causing catastrophic decompensation, requiring the patient to undergo cardiopulmonary bypass with emergency embolectomy.

Case Report

A 44-year-old female initially presented in March 2011 with gross haematuria and left flank pain, and workup revealed a heterogeneous 6 x 5 cm left upper pole renal mass. A metastatic evaluation was negative. The patient had no prior medical or surgical history and was a non-smoker. Anxious with her diagnosis, she elected to have an elective laparoscopic nephrectomy performed at the earliest available time. An abdominopelvic CT scan with IV contrast (Figure 1) done two weeks prior to date of surgery showed the tumor without any extensive invasion outside of the kidney and with only an element of left renal vein involvement, that id extend into the vena cava. In fact, the edge of the tumor thrombus was about 1.5 cm from the IVC.
The patient underwent a left laparoscopic radical nephrectomy in April 2011 in the standard manner. After placing the patient in the right lateral decubitus position and creating the pneumoperitoneum, surgery proceeded uneventfully until dissection of the renal hilum. The left renal artery was identified and stapled without difficulty. The left gonadal, adrenal, and lumbar veins were all identified and ligated. The left renal vein was then dissected and a vascular stapler was slowly closed flush to the IVC and then pushed laterally towards the kidney before closing completely and firing. Immediately after firing the vascular stapler, the patient became bradycardic, hypotensive, and hypoxic, eventually leading to PEA. A catastrophic event was suspected and the surgery immediately ceased with deflation of the pneumoperitoneum, removal of all laparoscopic ports, and placement of the patient in the supine position. Although a tension pneumothorax was initially suspected, TEE confirmed significant right ventricular (RV) distension and signs of pulmonary embolism. Aggressive cardiopulmonary resuscitation began and cardiothoracic surgery was emergently consulted for cardiopulmonary bypass and embolectomy.
A femoral-femoral bypass was established and a standard sternotomy was performed with the pericardium opened. The RV was significantly dilated and there was high pulmonary arterial pressure by palpation. The right atrium (RA) and ascending aorta were both cannulated and the femoral lines were switched to the aortic arterial line and venous outflow from the RA to reestablish bypass. The patient was then systemically cooled to approximately 31 degrees Celsius. The pulmonary artery was then opened in a longitudinal direction and multiple clots as well as tumor thrombi were then removed from all the pulmonary arterial segmental branches on both the left and right sides (Figure 2). A frozen section sent off revealed spindle cell tumor. After all clots and tumors had been removed, the pulmonary artery was closed along with the chest, while keeping a chest tube in place. The nephrectomy was completed by making a left subcostal incision and removing the entire left kidney. A JP drain was left in place and the abdomen was then closed.
The patient remained intubated in the ICU and was weaned off the ventilator on post-operative day three. The rest of her hospitalization was complicated by acute renal failure, from which she was able to recover. Upper extremity DVT also developed, for which she was placed on therapeutic enoxaparin. The patient was ultimately discharged from the hospital to begin outpatient chemotherapy with adriamycin, ifosfomide, mesna (AIM). Pathological confirmation of primary monophasic synovial sarcoma of the kidney was obtained, with molecular studies detecting SYT-SSX2 fusion transcripts consistent with t(X,18) translocation. Although the fascial margins of the tumor were negative, there was extensive lymphovascular invasion and extension into the renal sinus. Final pathology of the pulmonary thrombi demonstrated metastatic synovial sarcoma.
A PET scan done a month after patient’s operation revealed extensive areas of hypermetabolic nodules and soft tissue densities in the left renal bed and significant lymphadenopathy in the retroperitoneum coursing down the left ureter consistent with metastatic spread of the cancer. A repeat CT scan of the chest also revealed a non-occlusive filing defect at the bifurcation of the right main pulmonary artery suggesting in situ thrombus, as well as new lytic osseous lesions in the intervertebral bodies suspicious for osseous metastases.

Discussion

Primary synovial sarcoma of the kidney is rare and tumors presenting with IVC thrombus are fewer still-there are only four cases reported in the literature [4]. Our case is the first report of a PSS thrombus dislodging and embolizing the pulmonary arterial tree, causing immediate decompensation and requiring emergency sternotomy and embolectomy after placing the patient on cardiopulmonary bypass. The case is especially interesting and highlights the aggressiveness of this tumor variant because only two weeks prior to surgery, a CT scan showed a grossly patent IVC with minimal tumor invasion of the left renal vein. There was a wide discrepancy between the amount of tumor burden removed from the pulmonary arteries and the small tumor thrombus in the renal vein identified on CT scan. A case may have been made for additional imaging (MRI) to better define the level of tumor thrombus. However, recent literature shows that CT and MRI both detect and assess caval thrombus with similar sensitivity and specificity –78% and 72%, 88% and 76%, respectively [6]. In retrospect, we could have used an intra-operative ultrasound to better delineate the exact edge of the tumor thrombus in the renal vein prior to ligation. We did not because of the grossly patent IVC on recent imaging and because the attending surgeon felt confident in his technique of closing the stapler partway and then “milking” any thrombus away from the IVC before firing.
There is no preoperative method to diagnose PSS without tissue samples for analysis. Differential diagnosis includes adult Wilms tumor, renal cell carcinomas, mesoblastic nephromas, primitive neuroectodermal tumors, primary renal rhabdosarcomas, and transitional cell carcinomas. Using reverse transcriptase polymerase chain reaction (RT-PCR), Argani et al. were able to identify the presence of SYT-SSX gene fusion from t(X; 18) [2]. Although five different variants of the SSX gene have been identified, only SSX1 and SSX2 have been shown to fuse with the SYT gene to create the biphasic and monophasic forms of PSS, respectively. Biphasic PSS contains both glandular and spindle epithelial elements while the monophasic form is only composed of spindle cells [4, 7]. The only consistent immunoreactive marker for PSS is vimentin, which was markedly positive in our patient’s tumor.
Although surgery is the mainstay of therapy, it is not enough alone to augment the already poor prognosis associated with renal PSS. Although there have been limited success with stereotactic body radiotherapy and ifosamide and doxorubicin-based chemotherapy with case reports showing complete remission after post-nephrectomy metastasis to the lung, most patients do not live beyond two years [8, 9, 10].

070fig1

 

 

 

 

 

 

 

Fig. 1

070fig2

 

 

 

 

 

 

Fig. 2

References

1. Faria P, Argani P, Epstein J. Primary synovial sarcoma of the kidney: A molecular subset of so called embryonal renal sarcoma. Mod Pathol Am. 1999;12:94.
2. Argani P, Faria PA, Epstein JI, Reuter VE, Perlman EJ, Beckwith JB, Ladanyi M. Primary renal synovial sarcoma: molecular and morphologic delineation of an entity previously included among embryonal sarcomas of the kidney. Am J Surg Pathol. 2000 Aug;24(8):1087-96.
3. Gabilondo F, Rodríguez F, Mohar A, Nuovo GJ, Domínguez-Malagón H. Primary synovial sarcoma of the kidney: corroboration with in situ polymerase chain reaction. Ann Diagn Pathol. 2008;12:134-7.
4. Dassi V, Das K, Singh BP, Swain SK. Primary synovial sarcoma of kidney: A rare tumor with an atypical presentation. Indian J Urol. 2009 Apr-Jun;25(2): 269-271.
5. Kataria T, Janardhan N, Abhishek A, Sharan GK, Mitra S. Pulmonary metastasis from renal synovial sarcoma treated by stereotactic body radiotherapy: a case report and review of the literature. J Cancer Res Ther. 2010 Jan-Mar;6(1):75-9.
6. Hallscheidt PJ, Fink C, Haferkamp A, Bock M, Luburic A, Zuna I, Noeldge G, Kauffmann G. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. J Comput Assist Tomogr. 2005 Jan-Feb;29(1):64-8.
7. Skytting B, Nilsson G, Brodin B, Xie Y, Lundeberg J, Uhlen M, et al. A novel fusion gene, SYT-SSX4: In synovial sarcoma. J Natl Cancer Inst. 1999;91:974-5.
8. Kataria T, Janardhan N, Abhishek A, Sharan GK, Mitra S. Pulmonary metastasis from renal synovial sarcoma treated by stereotactic body radiotherapy: a case report and review of the literature. J Cancer Res Ther. 2010 Jan-Mar;6(1):75-9.
9. Park SJ, Kim HK, Kim CK, Park SK, Go ES, Kim ME, et al. A case of renal synovial sarcoma: Complete remission was induced by chemotherapy with Doxorubicin and Ifosamide. Korean J Intern Med. 2004;19:62-5.
10. Long JA, Dinia EM, Saada-Sebag G, Cyprien J, Pasquier D, Thuillier C, Terrier N, Boillot B, Descotes JL, Rambeaud JJ. Primitive renal synovial sarcoma: a cystic tumor in young patients. Prog Urol. 2009 Jul;19(7):474-8.

 

Date added to bjui.org: 26/11/2012

DOI: 10.1002/BJUIw-2012-070-web

 

© 2024 BJU International. All Rights Reserved.